Table 3.
Toxicity profile of lenalidomide in clinical trials for T-cell lymphomas
|
Toxicity/Adverse event
|
Ishida et al[44]
|
Querfeld et al[52]
|
Morschhauser et al[51]
|
Toumishey et al[57]
|
| Hematological toxicity | ||||
| Anemia total | 54% | 41% | NR | 26% |
| Anemia grade 3-4 | 19.2% | / | 4% | 11% |
| Leukopenia total | 50% | 22% | NR | NR |
| Leukopenia grade 3-4 | 38.5% | 3% | 4% | NR |
| Neutropenia total | 73% | NR | NR | 18% |
| Neutropenia grade 3-4 | 65.4% | NR | 15% | 16% |
| Thrombocytopenia total | 77% | NR | NR | 26% |
| Thrombocytopenia grade 3-4 | 23.1% | NR | 20% | 5% |
| Hypoalbuminemia | 35% | 28% | NR | NR |
| Grade 3-4 | / | / | NR | NR |
| Constipation | 31% | 34%1 | 17% | 44% |
| Grade 3-4 | / | / | NR | 3% |
| Nausea | 23.1% | 13% | NR | 28% |
| Grade 3-4 | 3.8% | / | NR | / |
| Vomiting | 23.1% | NR | NR | 10% |
| Grade 3-4 | / | NR | NR | / |
| Skin rash | 23.1% | 25% | NR | 38% |
| Grade 3-4 | 7.6% | / | 9% | 11% |
| Fatigue | 15.4% | 59% | NR | 56% |
| Grade 3-4 | 3.8% | 22% | NR | 11% |
| Diarrhea | NR | NR | NR | 31% |
| Grade 3-4 | NR | NR | NR | 8% |
| Pain | NR | 34% | NR | 64% |
| Grade 3-4 | NR | / | NR | 21% |
| Infection | 19.2% | 34% | NR | 26% |
| Grade 3-4 | 10.4% | 9% | 15% | 5% |
| Neuropathy | NR | 19% | NR | NR |
| Grade 3-4 | NR | / | NR | NR |
| Lower leg edema | NR | 47% | NR | 28% |
| Grade 3-4 | NR | / | NR | 3% |
| Anorexia | NR | 16% | NR | 28% |
| Grade 3-4 | NR | / | NR | 5% |
| Respiratory disorders | 10.4% | NR | NR | 26% |
| Grade 3-4 | 7.6% | NR | 13% | 13% |
| Pulmonary embolism | NR | NR | NR | 10% |
| Grade 3-4 | NR | NR | NR | 8% |
| Tumor flare reaction | NR | 28% | 14% | NR |
| Grade 3-4 | NR | NR | 4% | NR |
1
Considered together with diarrhea; Gastrointestinal disorders. NR: Not reported.